Neuroendocrine Substrates, Candidate Genes and Endophenotypes in ADHD
NCT02392169 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2015-03-18
Summary
Attention-deficit/hyperactivity disorder (ADHD) is one of the most common child and adolescent psychiatric disorders. In recent years, some researchers have become interested in analyzing neuroendocrine substrate levels in ADHD, including dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEA-S), cortisol and testosterone. Previous work in ADHD has established a strong heritable component to the phenotype. The STS gene, SULT2A1 gene and TH gene are associated with the function of DHEA/DHEA-S, and the NR3C1 gene is associated with the regulation of cortisol. Therefore, the relationship between these genes and the etiology of ADHD warrants investigation. Moreover, compared to the phenotype, the endophenotypes of ADHD may be more capable of detecting the underlying neurobiological and hereditary mechanisms. Therefore, this study aims to investigate the relationships between neuroendocrine substrates (DHEA, DHEA-S, cortisol and testosterone), candidate genes (STS gene, SULT2A1 gene, TH gene and NR3C1 gene) and the phenotype and endophenotypes (disease subtypes, neurocognitive function and response to treatment) of ADHD.
To complete this work, we will recruit 300 patients with ADHD (probands) and 600 biological parents of the probands. DNA will be extracted from buccal cells by cheek swab. At baseline, saliva samples of ADHD patients will be collected between 7:00 and 8:00 am using the passive drool method, to analyze the levels of neuroendocrine substrates. The patients will undergo assessment for their clinical symptoms and neurocognitive function. Methylphenidate will then be administered to the patients and the usual practice followed. At week 4 and week 52, procedures similar to those performed at baseline will be repeated.
The results of this study may further elucidate the complexity of the pathophysiology of ADHD. We may determine whether the neuroendocrine system, which contains levels of neuroendocrine substrates and associated genes, plays a crucial role in the phenotype and endophenotypes of ADHD. The information may serve as an important reference for the direction of future study and clinical treatment for patients with ADHD.
Conditions
- Attention Deficit Hyperactivity Disorder
Interventions
- DRUG
-
Methylphenidate
Patients used Retina or Concerta twice a day lasting for one year.
Sponsors & Collaborators
-
Chang Gung Memorial Hospital
lead OTHER
Principal Investigators
-
Liang-Jen Wang, MD, MPH · Chang Gung Memorial Hospital, Kaohsiung, Taiwan
Eligibility
- Min Age
- 6 Years
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-08-31
- Primary Completion
- 2017-07-31
- Completion
- 2017-07-31
Countries
- Taiwan
Study Locations
More Related Trials
-
Epigenetics in ADHD
NCT04860024 ·Status: COMPLETED
-
Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD
NCT02074228 ·Status: UNKNOWN ·Phase: PHASE4
-
Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD
NCT01682915 ·Status: COMPLETED
-
Candidate Gene Screening for Attention Deficit/Hyperactive Disorder (ADHD)
NCT03018574 ·Status: COMPLETED
-
Molecular Studies on the Candidate Genes of Dopaminergic and Noradrenergic Systems in ADHD
NCT00756158 ·Status: COMPLETED
-
Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD
NCT06073470 ·Status: RECRUITING
-
A Longitudinal Follow-up Study of Neuroimage and Neuropsychological Endophenotype Study on ADHD
NCT03679403 ·Status: COMPLETED
-
Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder
NCT02074176 ·Status: UNKNOWN
-
Inhibition Control of Children and Adolescents With ADHD
NCT01677819 ·Status: COMPLETED
-
The Role of Adverse Environment Factors, Family Functioning and Parental Psychopathology in the Response to Treatment With Methylphenidate in Children and Adolescents With Attention Deficit/Hyperactivity Disorder
NCT00773916 ·Status: COMPLETED ·Phase: PHASE4
-
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6
NCT04366609 ·Status: COMPLETED
-
Stimulant Effects on Brain Activity
NCT02453698 ·Status: COMPLETED ·Phase: PHASE1
-
Methylphenidate Treatment Response Study of Genetic Polymorphism in Attention Deficit Hyperactivity Disorder(ADHD)
NCT00862108 ·Status: UNKNOWN ·Phase: PHASE4
-
Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With ADHD
NCT02232464 ·Status: COMPLETED
-
New Technologies to Help Manage ADHD
NCT02390791 ·Status: COMPLETED ·Phase: NA
-
A Multi-dimensional Prospective Study to Discover Gene-microenvironment Interactions in Neurodevelopmental Disorders
NCT04878575 ·Status: RECRUITING
-
Carnitine as an Adjunct to Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder
NCT01099072 ·Status: UNKNOWN ·Phase: PHASE2
-
Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD
NCT02430896 ·Status: UNKNOWN
-
Examining Tolerance to CNS Stimulants in ADHD
NCT02039908 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolic Pathway of Tryptophan and Executive Dysfunction in Children With Attention Deficit Hyperactivity Disorder
NCT03901859 ·Status: UNKNOWN
-
Multimodal Neurobiological Approaches to Explore the Gene-Environment Interactions in ADHD
NCT04571125 ·Status: COMPLETED
-
Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder
NCT01130467 ·Status: UNKNOWN
-
Screening for Attention-deficit/Hyperactivity Disorder (ADHD) in Adolescent and Adult High Risk Populations
NCT00745524 ·Status: COMPLETED
-
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
NCT00428792 ·Status: COMPLETED ·Phase: PHASE3
-
Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders
NCT00025779 ·Status: COMPLETED ·Phase: NA